We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance Details Study Criteria for Severe Liver Injury Risk
FDA Guidance Details Study Criteria for Severe Liver Injury Risk
July 30, 2009
Sponsors have been given laboratory measurements for use in clinical trials to assess a product’s potential to cause severe drug-induced liver injury (DILI) during product development.